Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pluri Inc. (PLUR : NSDQ)

• Company Description    Pluri Inc. is a biotechnology company. Its technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of medicine and climate change to food scarcity, animal cruelty and beyond. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is based in HAIFA, Israel. Number of Employees: 118

• Price / Volume Information    Yesterday's Closing Price: $5.41 Daily Weekly Monthly 20 Day Moving Average: 61,459 shares Shares Outstanding: 7.83 (millions) Market Capitalization: $42.37 (millions) Beta: 0.79 52 Week High: $7.13 52 Week Low: $3.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.81% 21.10% 12 Week 34.24% 12.92% Year To Date 26.55% 18.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 - HAIFA,L3 3508409 ISR ph: 972-74-710-8600 fax: 972-74-710-8787 investor.relations@pluristem.com https://pluri-biotech.com

• General Corporate Information    Officers Yaky Yanay - Chief Executive Officer and President Zami Aberman - Chairman Chen Franco-Yehuda - Chief Financial Officer; Treasurer and Secretary Rami Levi - Director Doron Birger - Director Peer Information Pluri Inc. (CORR.) Pluri Inc. (RSPI) Pluri Inc. (CGXP) Pluri Inc. (BGEN) Pluri Inc. (GTBP) Pluri Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 72942G203 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/17/25 Share - Related Items Shares Outstanding: 7.83 Most Recent Split Date: 4.00 (0.13:1) Beta: 0.79 Market Capitalization: $42.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/17/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 87.05 Price/Cash Flow: - Price / Sales: 35.52 EPS Growth vs. Year Ago Period: 6.93% vs. Previous Quarter: -77.36% Sales Growth vs. Year Ago Period: 501.41% vs. Previous Quarter: 130.81% ROE 06/30/25 - - 03/31/25 - -4,191.91 12/31/24 - -2,778.13 ROA 06/30/25 - - 03/31/25 - -85.40 12/31/24 - -83.61 Current Ratio 06/30/25 - - 03/31/25 - 4.81 12/31/24 - 5.04 Quick Ratio 06/30/25 - - 03/31/25 - 4.81 12/31/24 - 5.04 Operating Margin 06/30/25 - - 03/31/25 - -2,563.29 12/31/24 - -3,551.49 Net Margin 06/30/25 - - 03/31/25 - -2,563.29 12/31/24 - -3,551.49 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,789.02 12/31/24 - -2,437.04 Book Value 06/30/25 - - 03/31/25 - 0.06 12/31/24 - -0.52 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 51.65 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 98.10 12/31/24 - -

Powered by Zacks Investment Research ©